

From: [REDACTED]

Sent: 29 September 2009 17:11

To: TA Comm A

Hi

Many thanks for the opportunity to review Appraisal Consultation Document (ACD) and evaluation report

for the above appraisal.

At this stage Novartis have no comments to make

[REDACTED]

[REDACTED]

Novartis Pharmaceuticals UK Limited

Frimley Business Park

GB- Frimley/Camberley, Surrey GU16 7SR

Phone: + [REDACTED]

Cell: + [REDACTED]

Email : [REDACTED]

>

> NICE - Technology Appraisals <TACommA@nice.org.uk>

> 04/09/2009 16:45

>

> Please respond to

> "NICE - Technology Appraisals" <TACommA@nice.org.uk>

>

> To

>

> "Novartis Pharmaceuticals (UK) Ltd" <natasha.amos@novartis.com>

>

> cc

>

> Subject

>

> Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab,

> and infliximab [review]) for Crohn's disease

>

> 04/09/2009

>

- > NHS
- > National Institute for
- > Health and Clinical Excellence
- >
- > MidCity Place
- > 71 High Holborn
- > London
- > WC1V 6NA
- >
- > Tel: 0845 003 7780
- > Fax: 0845 003 7784
- >
- > [www.nice.org.uk](http://www.nice.org.uk)
- >
- > 4 September 2009
- >
- >
- >
- >
- >
- > Health Technology Appraisal
- >

> Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab,  
> and infliximab [review]) for Crohn's disease

>

> Appraisal Consultation Document

>

>

>

> Dear Consultees and Commentators

>

> You are invited to comment on the enclosed Appraisal Consultation

> Document (ACD) and evaluation report for the above appraisal.

>

>

> The Appraisal Committee is interested in receiving your comments on

> the ACD under the following general headings:

>

> i) Do you consider that all of the relevant evidence

> has been taken into account?

>

> ii) Do you consider that the summaries of clinical and

> cost effectiveness are reasonable interpretations of the evidence

> and that the preliminary views on the resource impact and

> implications for the NHS are appropriate?

>

> iii) Do you consider that the provisional recommendations

> of the Appraisal Committee are sound and constitute a suitable basis

> for the preparation of guidance to the NHS?

>

> iv) Are there any equality related issues that may need

> special consideration?

>

> If you wish to comment on the evaluation report, please do so under

> a separate heading to your comments on the ACD.

>

> We prefer to receive comments in electronic format, either by email to

> TACommA@nice.org.uk or on compact or floppy disk. Please use

> Microsoft Office software products. Comments sent by post should be

> addressed to Bijal Joshi, Technology Appraisal Project Manager, at

> the above address.

>

> Please note that your comments, along with a summary table of these

> comments and the action taken in response to them will be released

- > to consultees and commentators with the Final Appraisal
- > Determination (FAD) for this appraisal, and published on the
- > Institute's website.
- >
- > In line with the Guide to Technology Appraisals (April 2004;
- > sections 4.5.2.7 and 4.5.2.10), we do not expect you to submit any
- > information which is commercial in confidence or academic in
- > confidence with your comments on the ACD and evaluation report.
- >
- > In the light of comments received, the Appraisal Committee will
- > reconsider the ACD at a meeting on 22 October 2009. In order for
- > your views to be included in the papers for this meeting, your
- > comments must be submitted before 5pm on 5 October 2009.
- >
- > The ACD and evaluation report will be posted on the Institute's
- > website on 14 September 2009. People who are not formal consultees
- > or commentators for this appraisal can comment on the ACD through an
- > email link on the website. However, we do not wish to receive
- > comments from formal consultees and commentators via the website.
- > Please send your comments directly to the Technology Appraisal
- > Project Manager, either by email or by post.

>

> I must emphasise that the documents enclosed with this letter, and  
> their contents, are confidential until they are published on the  
> Institute's website. They are released to you only for the purpose  
> of informing the Appraisal Committee's consideration of this  
> technology. Accordingly, neither the documents nor their contents  
> should be divulged to anyone other than those individuals within  
> your organisation who need to see to them to enable you to prepare  
> your response. You must ensure that anyone to whom you show the  
> documents is aware of their confidentiality.

>

> The use of any information contained in the ACD to make investment  
> decisions regarding any shares or other securities, or the passing  
> of such information to someone else for such use, may constitute  
> insider dealing, which is a criminal offence under section 52 of the  
> Criminal Justice Act 1993. It may also be an offence to encourage  
> someone else to deal in shares or securities, the price of which  
> would be affected by the disclosure to the public of any information  
> contained in the ACD.

>

> Yours sincerely,

>

> Dr Carole Longson

> Director, Centre for Health Technology Evaluation

>

> Attached:

> Appraisal Consultation Document (ACD)

> Evaluation report

>

> The information contained in this message and any attachments is

> intended for the addressee(s) only. If you are not the addressee,

> you may not disclose, reproduce or distribute this message. If you

> have received this message in error, please advise the sender and

> delete it from your system. Any personal data sent in reply to this

> message will be used in accordance with provisions of the Data

> Protection Act 1998 and only for the purposes of the Institute's work.

>

> All messages sent by NICE are checked for viruses, but we recommend

> that you carry out your own checks on any attachment to this

> message. We cannot accept liability for any loss or damage caused by

> software viruses.

>



> <http://www.nice.org.uk>

>

> [attachment "Crohns ACD 2\_v9\_040909\_to PM.doc" deleted by

██████████

/██████████ [attachment "Evaluation Report.zip" deleted by

> ██████████/██████████ Novartis]

---

Delivered via MessageLabs

---